Deep Track Capital is an investment firm that focuses solely on the life sciences sector.
Deep Track Capital is an investment firm focused exclusively on the life sciences and biotech industry. It forges long-term partnerships with the management teams of leading innovative public and pre-IPO biotechnology companies. It seeks to invest its time and expertise, as well as its network, for the benefit of the partners in addition to capital. The firm intends to lead transactions while forming large syndicates, as well as to participate in rounds led by other qualified investors.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 7, 2022
Apogee Therapeutics
|
Series B | $149M | Biotechnology | Yes |
Sep 30, 2022
Valneva
|
Post-IPO Equity | €102.90M | Biotechnology | — |
Jan 25, 2022
Metagenomi
|
Series B | $175M | Artificial Intelligence | — |